Incyte

Incyte P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Incyte (INCY) as of Sep 24, 2026 is 14.85. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 80.78 — a change of -81.61% (lower).

P/FCF

14.85

YoY

-81.61%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Incyte is 2026 14.85 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Incyte was 2025 80.78 . It decreases by -81.61% lower compared to the previous year.

The Incyte P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
76.58 USD
Jan 1, 2019
31.81 USD
Jan 1, 2020
-64.49 USD
Jan 1, 2021
35.39 USD
Jan 1, 2022
22.55 USD
Jan 1, 2023
44.81 USD
Jan 1, 2024
80.78 USD
Jan 1, 2025
14.85 USD
The Incyte P/FCF history
YEARP/FCFYoY
14.85-81.61%
80.78+80.27%
44.81+98.69%
22.55-36.28%
35.39-154.88%
-64.49-302.77%
31.81-58.47%
76.58-177.65%
-98.62-190.43%
109.07-67.19%
332.39-102.68%
-12,419.98—
Access this data via the Eulerpool API

Incyte Stock analysis

What does Incyte do? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incyte stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Incyte is 14.85 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Incyte changed from 80.78 to 14.85, representing a -81.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Incyte since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Incyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Incyte

All Key Metrics — Incyte